Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects With Helicobacter Pylori Infection

NCT04198363 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04198363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04198363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects With Helicobacter Pylori Infection
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2020
Completion date
November 25, 2021
Enrollment
510 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori